FindTrial
Sign In

Study on Parkinson's disease and related disorders with dopamine transporter ligand [C-11]PE2I

Study on Parkinson's disease and related disorders with dopamine transporter ligand [C-11]PE2I - DAT PET with [C-11]PE2I in PD and related disorders

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000014709
Enrollment
200
Registered
2014-08-01
Start date
2014-07-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients of Parkinson&#39

Interventions

The dosage in the vein of [C-11]PE2I, [C-11]raclopride, and [F-18]FDG for PET/CT imaging.

Sponsors

Tokyo Metropolitan Institute of Gerontology
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. The subjects who has intention to participate in this study, and signed informed consent. 2. Male and female subjects of >=18 years old. 3. The subject who was judged by clinical investigator by means of physical examination and laboratory tests to be eligible as a participant in this study.

Exclusion criteria

Exclusion criteria: 1.The subject who has dysfunction in the liver / kidney. 2.The subject who has abnormal findings in the central nervous system other than the target disorders. 3.The subjects having cardiac failure. 4.The subject with a history of a drug or food allergy. 5.Pregnant or woman who has a chance of pregnant. 6.The subject who was judged by the clinical investigator to be inappropriate as a participant in this study.

Design outcomes

Primary

MeasureTime frame
Binding potential and tissue concentration ratio—

Countries

Japan

Contacts

Public ContactKenji Ishii

Tokyo Metropolitan Institute of Gerontology Research Team for Neuroimaging

ishii@pet.tmig.or.jp0339643241

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026